Chemistry:Zanolimumab
From HandWiki
Short description: Human monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 147 kg/mol |
  (what is this?) (verify) | |
Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.[1] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] Development of the drug was ultimately discontinued with termination of all trials.[5]
References
- ↑ "Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome". Expert Opinion on Biological Therapy 8 (12): 1929–39. December 2008. doi:10.1517/14712590802528696. PMID 18990079.
- ↑ "TenX BioPharma". http://www.tenxbiopharma.com/development.shtml.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ↑ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ↑ "Status of clinical trials for Zanolimumab". http://clinicaltrials.gov/search/intervention=Zanolimumab.
 |  |
